President Donald Trump issued an executive order Monday directing changes to childhood vaccination practices in the United States, specifically calling for the separation of combination vaccines—particularly the MMR shot for measles, mumps, and rubella—into individual injections and for spacing out vaccination appointments whenever possible.
The order instructs federal officials to develop plans within 90 days for implementing these changes. To accomplish the unbundling, pharmaceutical manufacturers would need to revive individual vaccines that have not been widely produced in the U.S. for decades and construct new manufacturing facilities capable of producing millions of additional doses. Industry experts note that designing, constructing, and obtaining federal approval for new vaccine plants typically requires approximately five years. Companies would also likely need to conduct extensive studies demonstrating that newly formulated individual shots produce comparable immune responses to current versions, and the Food and Drug Administration would be required to license each unbundled vaccine separately—a process without precedent.
For families, the changes would substantially increase the number of doctor visits required. Under the current system, the MMR vaccine is administered in two doses, but splitting it into three separate components would require six office visits alone. Spacing out additional vaccines for other diseases would multiply visits further. Public health experts warn this increased inconvenience could lead parents to miss appointments or discontinue vaccinations, potentially reducing overall immunization rates. The approach would also generate additional costs for syringes, medical supplies, and healthcare provider time, while straining pediatricians’ schedules.
Public health researchers have expressed strong opposition to the directive. Officials from Johns Hopkins and Georgetown University stated there is no scientific basis for the changes, and major vaccine manufacturers including Merck and GSK affirmed the safety and effectiveness of combination vaccines. The order faces significant practical obstacles: neither the White House nor the FDA can compel drugmakers to develop new vaccines, and companies have limited financial incentive to create individual versions that would compete with their existing combination products. Additionally, only state governments possess legal authority to mandate vaccinations, and experts suggested states may disregard the administration’s advisory to update vaccination requirements.
The order reflects longstanding positions Trump has advocated for more than a decade, though medical organizations have rejected these views. White House officials argued the changes would provide parents more options and increase vaccination rates, while critics contend the approach would achieve the opposite effect.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI